远隔效应可能增强难治性经典型霍奇金淋巴瘤中PD-1抑制作用。 - Suppr | 超能文献

相似文献

1

An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.远隔效应可能增强难治性经典型霍奇金淋巴瘤中PD-1抑制作用。

Leuk Lymphoma. 2018 Nov;59(11):2749-2751. doi: 10.1080/10428194.2018.1452217. Epub 2018 Mar 23.

2

[Not Available].[无可用内容]

Bull Cancer. 2018 Dec;105 Suppl 1:S50-S58. doi: 10.1016/S0007-4551(18)30390-4.

3

Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.抗程序性死亡蛋白1（PD-1）免疫疗法联合序贯受累部位放疗用于多次预处理的难治性霍奇金淋巴瘤治疗

Cancer Radiother. 2019 Apr;23(2):132-137. doi: 10.1016/j.canrad.2018.05.002. Epub 2019 Feb 4.

4

Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience.纳武利尤单抗在复发/难治性经典型霍奇金淋巴瘤中诱导出显著疗效：单中心经验。

J Oncol Pharm Pract. 2019 Oct;25(7):1586-1589. doi: 10.1177/1078155218800150. Epub 2018 Sep 26.

5

Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.尼伏鲁单抗与 T 细胞 PD-1 结合的丧失预示霍奇金淋巴瘤的复发。

Int J Hematol. 2020 Mar;111(3):475-479. doi: 10.1007/s12185-019-02737-4. Epub 2019 Sep 19.

6

Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma.低剂量纳武单抗诱导难治性经典型霍奇金淋巴瘤缓解。

Ann Hematol. 2017 Jul;96(7):1219-1220. doi: 10.1007/s00277-017-3007-9. Epub 2017 Apr 22.

7

Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies.在接受抗PD-1单克隆抗体治疗的霍奇金淋巴瘤患者中，使用18F-FDG PET/CT观察到的非常规免疫相关现象。

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1391-1392. doi: 10.1007/s00259-019-04310-x. Epub 2019 Mar 19.

8

PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.PD-1 阻断可诱导异基因造血干细胞移植后复发的经典霍奇金淋巴瘤缓解。

J Immunother Cancer. 2017 Feb 21;5:11. doi: 10.1186/s40425-017-0211-z. eCollection 2017.

9

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.霍奇金淋巴瘤患者停用抗程序性死亡蛋白1（anti-PD-1）治疗后出现长期缓解。

Blood. 2018 Jun 21;131(25):2856-2859. doi: 10.1182/blood-2018-03-841262. Epub 2018 May 3.

10

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的 PD-1 阻断作用。

N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

引用本文的文献

1

Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.靶向程序性死亡受体-1/程序性死亡配体-1的免疫检查点抑制剂在人类淋巴瘤治疗中的应用

Front Oncol. 2024 Jul 18;14:1420920. doi: 10.3389/fonc.2024.1420920. eCollection 2024.

2

Tumor Microenvironment and Microvascular Density in Follicular Lymphoma.滤泡性淋巴瘤中的肿瘤微环境与微血管密度

J Clin Med. 2022 Feb 25;11(5):1257. doi: 10.3390/jcm11051257.

3

Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?转移性癌症中的远隔效应：是否有可能采用预测性方法来改善个体治疗结果？